Press release
August 13, 2026
Aktis Oncology Reports Financial Results and Business Highlights for the Second Quarter 2026
Aktis Oncology, Inc. (AKTS)
Presented first-in-human clinical imaging and dosimetry data for AKY-2519, supporting a broad clinical development program in patients with prostate, lung, and other B7-H3 expressing solid tumors Enrolling patients in Phase 1b trial of AKY-1189 in locally advanced or metastatic urothelial cancer